SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN)

SG Americas Securities LLC decreased its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 88.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,860 shares of the company’s stock after selling 76,236 shares during the quarter. SG Americas Securities LLC’s holdings in Arvinas were worth $243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Arvinas during the 1st quarter valued at $44,000. Quest Partners LLC bought a new stake in Arvinas during the 2nd quarter valued at $42,000. Amalgamated Bank raised its holdings in Arvinas by 29.6% during the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock valued at $59,000 after acquiring an additional 508 shares during the period. Cullinan Associates Inc. bought a new stake in Arvinas during the 1st quarter valued at $248,000. Finally, Contravisory Investment Management Inc. bought a new position in shares of Arvinas in the second quarter worth $185,000. Institutional investors own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Arvinas in a report on Tuesday, July 30th. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price target on shares of Arvinas in a report on Thursday, August 1st. Barclays decreased their price target on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Finally, Oppenheimer decreased their price target on shares of Arvinas from $70.00 to $50.00 and set an “outperform” rating on the stock in a report on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Arvinas Stock Down 5.0 %

NASDAQ ARVN opened at $25.76 on Tuesday. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -4.34 and a beta of 1.97. The company has a 50-day simple moving average of $25.30 and a two-hundred day simple moving average of $28.30. Arvinas, Inc. has a 12-month low of $13.57 and a 12-month high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($1.08) by $0.59. The firm had revenue of $76.50 million for the quarter, compared to the consensus estimate of $33.27 million. The business’s revenue was up 40.4% on a year-over-year basis. During the same period last year, the company posted ($1.25) earnings per share. Equities analysts expect that Arvinas, Inc. will post -3.51 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.